These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21812019)

  • 41. Thromboembolic events with lenalidomide-based therapy for multiple myeloma.
    Menon SP; Rajkumar SV; Lacy M; Falco P; Palumbo A
    Cancer; 2008 Apr; 112(7):1522-8. PubMed ID: 18278812
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.
    Sher T; Miller KC; Lawrence D; Whitworth A; Hernandez-Ilizaliturri F; Czuczman MS; Miller A; Lawrence W; Bilgrami SA; Sood R; Wood MT; Block AW; Lee K; Chanan-Khan AA
    Leuk Lymphoma; 2010 Jan; 51(1):85-8. PubMed ID: 20055660
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
    Spina F; Rezzonico F; Farina L; Corradini P
    Eur J Haematol; 2013 Apr; 90(4):340-4. PubMed ID: 23281656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.
    Fiorcari S; Martinelli S; Bulgarelli J; Audrito V; Zucchini P; Colaci E; Potenza L; Narni F; Luppi M; Deaglio S; Marasca R; Maffei R
    Haematologica; 2015 Feb; 100(2):253-62. PubMed ID: 25398834
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.
    Strati P; Keating MJ; Wierda WG; Badoux XC; Calin S; Reuben JM; O'Brien S; Kornblau SM; Kantarjian HM; Gao H; Ferrajoli A
    Blood; 2013 Aug; 122(5):734-7. PubMed ID: 23801633
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of thrombosis with lenalidomide and its prevention with aspirin.
    Hirsh J
    Chest; 2007 Jan; 131(1):275-7. PubMed ID: 17218586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.
    Herman SE; Lapalombella R; Gordon AL; Ramanunni A; Blum KA; Jones J; Zhang X; Lannutti BJ; Puri KD; Muthusamy N; Byrd JC; Johnson AJ
    Blood; 2011 Apr; 117(16):4323-7. PubMed ID: 21378270
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
    Winqvist M; Mozaffari F; Palma M; Eketorp Sylvan S; Hansson L; Mellstedt H; Österborg A; Lundin J
    Cancer Immunol Immunother; 2017 Jan; 66(1):91-102. PubMed ID: 27815572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
    Bagratuni T; Kastritis E; Politou M; Roussou M; Kostouros E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanelias N; Terpos E; Dimopoulos MA
    Am J Hematol; 2013 Sep; 88(9):765-70. PubMed ID: 23757261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of patients with chronic lymphocytic leukemia treated with lenalidomide.
    Miller KC; Musial L; Whitworth A; Chanan-Khan A
    Clin J Oncol Nurs; 2010 Aug; 14(4):491-9. PubMed ID: 20682505
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.
    Lee BN; Gao H; Cohen EN; Badoux X; Wierda WG; Estrov Z; Faderl SH; Keating MJ; Ferrajoli A; Reuben JM
    Cancer; 2011 Sep; 117(17):3999-4008. PubMed ID: 21858802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
    Niesvizky R; Martínez-Baños D; Jalbrzikowski J; Christos P; Furst J; De Sancho M; Mark T; Pearse R; Mazumdar M; Zafar F; Pekle K; Leonard J; Jayabalan D; Coleman M
    Leuk Lymphoma; 2007 Dec; 48(12):2330-7. PubMed ID: 18067007
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?
    Brown JR
    Leuk Lymphoma; 2010 Aug; 51(8):1382-5. PubMed ID: 20624030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
    Maffei R; Colaci E; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
    Crit Rev Oncol Hematol; 2016 Jan; 97():291-302. PubMed ID: 26454471
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Age over 65 years and high levels of C-reactive protein are associated with the risk of preoperative deep vein thrombosis following closed distal femur fractures: a prospective cohort study.
    Zhang J; Zhao K; Li J; Meng H; Zhu Y; Zhang Y
    J Orthop Surg Res; 2020 Nov; 15(1):559. PubMed ID: 33239071
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.
    Vitale C; Falchi L; Ten Hacken E; Gao H; Shaim H; Van Roosbroeck K; Calin G; O'Brien S; Faderl S; Wang X; Wierda WG; Rezvani K; Reuben JM; Burger JA; Keating MJ; Ferrajoli A
    Clin Cancer Res; 2016 May; 22(10):2359-67. PubMed ID: 26733610
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Idiopathic venous thrombosis is related to systemic inflammatory response and to increased levels of circulating markers of endothelial dysfunction.
    Jezovnik MK; Poredos P
    Int Angiol; 2010 Jun; 29(3):226-31. PubMed ID: 20502419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.
    Riches JC; Gribben JG
    Curr Cancer Drug Targets; 2016; 16(8):689-700. PubMed ID: 27055579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
    Kater AP; Tonino SH; Egle A; Ramsay AG
    Blood; 2014 Oct; 124(14):2184-9. PubMed ID: 25161268
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
    Srinivasan S; Schiffer CA
    Leuk Res; 2009 Apr; 33(4):561-4. PubMed ID: 18676017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.